Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pembrolizumab, a humanized IgG4 monoclonal antibody targeting programmed death-1 protein, has demonstrated efficacy in relapsed/refractory classical Hodgkin lymphoma (cHL). To assess the complete metabolic response (CMR) rate and safety of pembrolizumab monotherapy in newly diagnosed cHL, we conduct...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Allen, Pamela B., Savas, Hatice, Evens, Andrew M., Advani, Ranjana H., Palmer, Brett, Pro, Barbara, Karmali, Reem, Mou, Eric, Bearden, Jeffrey, Dillehay, Gary, Bayer, Robert A., Eisner, Robert M., Chmiel, Joan S., O’Shea, Kaitlyn, Gordon, Leo I., Winter, Jane N.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2021
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7955404/
https://ncbi.nlm.nih.gov/pubmed/32992341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007400
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars